

GLAXOSMITHKLINE PLC  
Form 6-K  
January 17, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 16 January 2017

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Sir Andrew Witty
- b) Position/status Chief Executive Officer
- c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
- b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
- c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£15.66	406.772 (personal contribution)
£15.66	406.759 (personal contribution)
£15.66	203.865 (personal contribution)
£15.66	203.865 (personal contribution)
£15.66	510.713 (personal contribution)
£15.66	406.772 (matching shares)
£15.66	406.759 (matching shares)
£15.66	203.865 (matching shares)

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

£15.66 203.865 (matching shares)

£15.66 510.713 (matching shares)

d) Aggregated information 3,463.948  
 Aggregated volume Price £15.66

e) Date of the transaction 2017-01-12

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms E Walmsley

b) Position/status CEO Designate

c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform,  
 auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument;  
 (ii) each type of transaction; (iii) each date; and (iv) each place where  
 transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each  
 ('Ordinary Shares')  
 ISIN: GB0009252882

b) Nature of the transaction Increase in notional interest in Ordinary  
 Shares following the re-investment of  
 dividends paid to shareholders on 12  
 January 2017 on Ordinary Shares held in  
 the Company's 2009 Deferred Annual  
 Bonus Plan.

Price(s) Volume(s)

£15.66 89.065 (personal contribution)

£15.66 89.065 (personal contribution)

£15.66 71.015 (personal contribution)

c) Price(s) and volume(s)

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

£15.66 71.015 (personal contribution)  
 £15.66 175.863 (personal contribution)  
 £15.66 175.850 (personal contribution)  
 £15.66 89.065 (matching shares)  
 £15.66 89.065 (matching shares)  
 £15.66 71.015 (matching shares)  
 £15.66 71.015 (matching shares)  
 £15.66 175.863 (matching shares)  
 £15.66 175.850 (matching shares)

d) Aggregated information 1,343.746  
 Aggregated volume Price £15.66  
 e) Date of the transaction 2017-01-12  
 f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr R G Connor  
 b) Position/status President, Global Manufacturing & Supply  
 c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
 ISIN: GB0009252882

b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

Price(s) Volume(s)

£15.66 79.620 (personal contribution)

£15.66 79.607 (personal contribution)

£15.66 52.007 (personal contribution)

£15.66 52.007 (personal contribution)

c) Price(s) and volume(s) £15.66 119.484 (personal contribution)

£15.66 79.620 (matching shares)

£15.66 79.607 (matching shares)

£15.66 52.007 (matching shares)

£15.66 52.007 (matching shares)

£15.66 119.484 (matching shares)

d) Aggregated information 765.45

Aggregated volume Price £15.66

e) Date of the transaction 2017-01-12

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr S Dingemans

b) Position/status Chief Financial Officer

c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument;  
 3. (ii) each type of transaction; (iii) each date; and (iv) each place where  
 transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each  
 ('Ordinary Shares')  
 ISIN: GB0009252882

b) Nature of the transaction Increase in notional interest in Ordinary  
 Shares following the re-investment of  
 dividends paid to shareholders on 12  
 January 2017 on Ordinary Shares held in  
 the Company's 2009 Deferred Annual  
 Bonus Plan.

Price(s) Volume(s)

£15.66 192.213 (personal contribution)

£15.66 76.874 (personal contribution)

£15.66 99.193 (personal contribution)

£15.66 99.180 (personal contribution)

£15.66 232.242 (personal contribution)

c) Price(s) and volume(s) £15.66 232.229 (personal contribution)

£15.66 192.213 (matching shares)

£15.66 76.874 (matching shares)

£15.66 99.193 (matching shares)

£15.66 99.180 (matching shares)

£15.66 232.242 (matching shares)

£15.66 232.229 (matching shares)

d) Aggregated information 1,863.862  
 Aggregated volume Price £15.66

e) Date of the transaction 2017-01-12

f) Place of the transaction n/a

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr N Hirons
- b) Position/status SVP, Global Ethics & Compliance
- c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
- b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
- c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£15.66	36.414 (personal contribution)
£15.66	36.414 (personal contribution)
£15.66	85.869 (personal contribution)
£15.66	85.869 (personal contribution)
£15.66	36.414 (matching shares)
£15.66	36.414 (matching shares)
£15.66	85.869 (matching shares)
£15.66	85.869 (matching shares)
- d) Aggregated information 489.132  
Aggregated volume Price £15.66

e) Date of the transaction 2017-01-12

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr S A Hussain

b) Position/status President, Global Pharmaceuticals

c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

Price(s) Volume(s)

£15.66 116.783 (personal contribution)

£15.66 171.654 (personal contribution)

£15.66 202.916 (personal contribution)

c) Price(s) and volume(s) £15.66 202.916 (personal contribution)

£15.66 116.783 (matching shares)

£15.66 171.654 (matching shares)



Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

£15.66 202.916 (matching shares)

£15.66 202.916 (matching shares)

d) Aggregated information 1,388.538  
 Aggregated volume Price £15.66

e) Date of the transaction 2017-01-12

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr D S Redfern

b) Position/status Chief Strategy Officer

c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
 ISIN: GB0009252882

b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

Price(s) Volume(s)

£15.66 72.618 (personal contribution)

£15.66 72.605 (personal contribution)

£15.66 58.351 (personal contribution)

c) Price(s) and volume(s)

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

£15.66 58.351 (personal contribution)  
 £15.66 109.284 (personal contribution)  
 £15.66 109.284 (personal contribution)  
 £15.66 72.618 (matching shares)  
 £15.66 72.605 (matching shares)  
 £15.66 58.351 (matching shares)  
 £15.66 58.351 (matching shares)  
 £15.66 109.284 (matching shares)  
 £15.66 109.284 (matching shares)

d) Aggregated information 960.986  
 Aggregated volume Price £15.66

e) Date of the transaction 2017-01-12

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Dr M M Slaoui  
 b) Position/status Chairman, Global Vaccines  
 c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument American Depositary Shares ('ADSs')  
 ISIN: US37733W1053  
 b) Nature of the transaction Increase in notional interest in ADSs  
 following the re-investment of dividends

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

paid to shareholders on 12 January 2017  
on ADSs held in the Company's 2009  
Deferred Annual Bonus Plan.

Price(s) Volume(s)

\$39.01 125.340 (personal contribution)

\$39.01 125.327 (personal contribution)

\$39.01 78.047 (personal contribution)

\$39.01 78.047 (personal contribution)

\$39.01 128.475 (personal contribution)

c) Price(s) and volume(s) \$39.01 128.475 (personal contribution)

\$39.01 125.340 (matching shares)

\$39.01 125.327 (matching shares)

\$39.01 78.047 (matching shares)

\$39.01 78.047 (matching shares)

\$39.01 128.475 (matching shares)

\$39.01 128.475 (matching shares)

d) Aggregated information 1,327.422  
Aggregated volume Price \$39.01

e) Date of the transaction 2017-01-12

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms C Thomas

b) Position/status SVP, Human Resources

c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform,  
auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument;  
 3. (ii) each type of transaction; (iii) each date; and (iv) each place where  
 transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each  
 ('Ordinary Shares')  
 ISIN: GB0009252882

b) Nature of the transaction Increase in notional interest in Ordinary  
 Shares following the re-investment of  
 dividends paid to shareholders on 12  
 January 2017 on Ordinary Shares held in  
 the Company's 2009 Deferred Annual  
 Bonus Plan.

	Price(s)	Volume(s)
	£15.66	90.103 (personal contribution)
	£15.66	78.542 (personal contribution)
	£15.66	78.530 (personal contribution)
	£15.66	159.879 (personal contribution)
c) Price(s) and volume(s)	£15.66	159.879 (personal contribution)
	£15.66	90.103 (matching shares)
	£15.66	78.542 (matching shares)
	£15.66	78.530 (matching shares)
	£15.66	159.879 (matching shares)
	£15.66	159.879 (matching shares)

d) Aggregated information 1,133.866  
 Aggregated volume Price £15.66

e) Date of the transaction 2017-01-12

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr P C Thomson

b) Position/status SVP, Communications & Government Affairs

c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c) Price(s) and volume(s) Price(s) Volume(s)  
£15.66 54.266 (personal contribution)

£15.66 53.347 (personal contribution)

c) Price(s) and volume(s) £15.66 97.819 (personal contribution)

£15.66 54.266 (matching shares)

£15.66 53.347 (matching shares)

£15.66 97.819 (matching shares)

d) Aggregated information 410.864  
Aggregated volume Price £15.66

e) Date of the transaction 2017-01-12

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr D E Troy
- b) Position/status SVP & General Counsel
- c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument American Depositary Shares ('ADSs')  
ISIN: US37733W1053

- b) Nature of the transaction Increase in notional interest in ADSs  
following the re-investment of dividends  
paid to shareholders on 12 January 2017  
on ADSs held in the Company's 2009  
Deferred Annual Bonus Plan.

Price(s) Volume(s)

- \$39.01 50.726 (personal contribution)
- \$39.01 50.726 (personal contribution)
- \$39.01 40.386 (personal contribution)
- \$39.01 40.386 (personal contribution)
- \$39.01 90.932 (personal contribution)
- c) Price(s) and volume(s) \$39.01 90.932 (personal contribution)
- \$39.01 50.726 (matching shares)
- \$39.01 50.726 (matching shares)
- \$39.01 40.386 (matching shares)
- \$39.01 40.386 (matching shares)

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

\$39.01 90.932 (matching shares)

\$39.01 90.932 (matching shares)

d) Aggregated information 728.176  
 Aggregated volume Price \$39.01

e) Date of the transaction 2017-01-12

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Dr P J T Vallance

b) Position/status President, Pharmaceuticals R&D

c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform,  
 auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument;  
 (ii) each type of transaction; (iii) each date; and (iv) each place where  
 transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each  
 ('Ordinary Shares')  
 ISIN: GB0009252882

b) Nature of the transaction Increase in notional interest in Ordinary  
 Shares following the re-investment of  
 dividends paid to shareholders on 12  
 January 2017 on Ordinary Shares held in  
 the Company's 2009 Deferred Annual  
 Bonus Plan.

Price(s) Volume(s)

£15.66 161.014 (personal contribution)

£15.66 161.001 (personal contribution)

£15.66 115.614 (personal contribution)

c) Price(s) and volume(s)

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

£15.66 115.614 (personal contribution)

£15.66 188.068 (personal contribution)

£15.66 188.068 (personal contribution)

£15.66 161.014 (matching shares)

£15.66 161.001 (matching shares)

£15.66 115.614 (matching shares)

£15.66 115.614 (matching shares)

£15.66 188.068 (matching shares)

£15.66 188.068 (matching shares)

d) Aggregated information 1,858.758  
Aggregated volume Price £15.66

e) Date of the transaction 2017-01-12

f) Place of the transaction n/a

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc

(Registrant)

Date: January 16, 2017

By: VICTORIA WHYTE-

-----

Victoria Whyte

Authorised Signatory for and on

behalf of GlaxoSmithKline plc



